Product
Neoadjuvant therapy before radical nephrectomy
1 clinical trial
2 indications
Indication
Bladder CancerIndication
CancerClinical trial
Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients With Operable, High-risk, Localized Urothelial Carcinoma of the Upper Urinary TractStatus: Recruiting, Estimated PCD: 2025-01-01